CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net sales	$ 5,439.5	$ 5,010.0	$ 4,464.0
Cost of sales	1,117.5	978.4	723.7
Gross profit	4,322.0	4,031.6	3,740.3
Selling, general, and administrative expenses	1,789.2	1,582.5	1,357.6
Research and development expenses	1,053.0	962.9	843.6
Intellectual property agreement and certain litigation expenses (Note 3)	40.4	203.5	15.8
Change in fair value of contingent consideration liabilities (Note 13)	0.0	(26.2)	(35.8)
Restructuring charges, separation costs, and other (Note 4)	61.0	0.0	60.7
Other operating income, net	(0.3)	0.0	0.0
Operating income	1,378.7	1,308.9	1,498.4
Interest expense	19.8	17.6	19.2
Interest income	(120.3)	(67.2)	(35.5)
Other non-operating income, net (Note 18)	(68.9)	(13.9)	(4.8)
Income from continuing operations before provision for income taxes	1,548.1	1,372.4	1,519.5
Provision for income taxes (Note 19)	152.1	152.4	195.5
Net income from continuing operations	1,396.0	1,220.0	1,324.0
Income from discontinued operations, net of tax	2,773.7	179.4	197.9
Net income	4,169.7	1,399.4	1,521.9
Net loss attributable to noncontrolling interest	(4.9)	(3.0)	0.0
Net income attributable to Edwards Lifesciences Corporation.	$ 4,174.6	$ 1,402.4	$ 1,521.9
Basic
Continuing operations (in dollars per share)	$ 2.34	$ 2.02	$ 2.14
Discontinued operations (in dollars per share)	4.64	0.29	0.32
Basic earnings per share (in dollars per share)	6.98	2.31	2.46
Diluted:
Continuing operations (in dollars per share)	2.34	2.01	2.12
Discontinued operations (in dollars per share)	4.63	0.29	0.32
Diluted earnings per share (in dollars per share)	$ 6.97	$ 2.30	$ 2.44
Weighted-average number of common shares outstanding attributable to Edwards Lifesciences Corporation:
Basic (in shares)	597.7	606.7	619.0
Diluted (in shares)	599.3	609.4	624.2